• Our Vision is to improve healthcare as a global provider of innovative and reliable diagnostic tests.
  • Our Mission is to identify and develop novel patentable diagnostic markers and technologies which can be commercialised to meet clinical needs.
  • We will collaborate with partners, create branded products and identify complementary businesses which support our objective of continuing to grow as a respected and profitable healthcare company.
  • Our Values include meeting all current and future regulatory, quality and environmental standards appropriate for our industry and the countries in which we operate.

Cardiovascular disease (CVD) is the leading cause of mortality in the western world, accounting for over 40% of total deaths each year.

Up to 70% of individuals who develop heart attacks have normal levels of cholesterol, a test widely recognised as an indicator of coronary artery disease, so it is clear other factors besides plasma lipids are involved in many forms of this disease.

The medical community recognises that there is a need for better indicators of CVD risk. The cost to monitor and treat patients suffering from CVD, including heart attacks and other cardiac events such as strokes is enormous. According to the American Heart Association (AHA), the total financial cost of CVD and strokes in the US alone during 2001 was estimated at over $298 billion.

The causes of CVD are multifactorial and we are therefore working on the development of a number of different products to assess CVD risk. We believe that these new markers will ultimately provide medical practitioners with the information they need to prescribe the most efficacious and cost effective therapies, the result being a healthier patient leading a more comfortable lifestyle and more efficient management of a chronic and potentially fatal disease. In the future we believe that early diagnosis and remedial action may be able to reduce the overall burden of cardiovascular disease.



Most of our business in this product area is derived from our assays for the measurement of Homocysteine. Elevated blood levels of this amino acid are believed to be a causal influence on the development of CVD and the subsequent likelihood of MI.

We have partnered with companies such as Abbott Laboratories, Siemens Healthcare Diagnostics and IL to produce assays for this important marker under OEM arrangements. Our clinical chemistry detection technology is also available for a number of proprietary analysers.

General news on Homocysteine can be found at www.homocysteine.org.uk.

Axis-Shield at a Glance

A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories.

› More about our tests

Focus on Homocysteine

As a general marker of overall health status, few tests carry greater predictive weight than Homocysteine. The amount of Homocysteine in your blood is one of the best independent indicators of how healthy you are.


› Axis-Shield Homocysteine assays

© Axis-Shield plc 2011. All rights reserved. Registered in Scotland No. SC145200 - Sitemap | Terms-of-Use | Accessibility | Disclaimer
Luna Place, The Technology Park, Dundee, DD2 1XA, Scotland.
Diagnostics for the laboratory & the point of care in areas of clinical need including diabetes, cardiovascular & neurodegenerative disease, rheumatoid arthritis & infectious disease.